CLINICAL_TRIALS
trial_result
· 2018-04-20
Clinical Trial Update: Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer [Phase 2]
Summary
Phase II trial of bortezomib and doxorubicin in metastatic breast cancer was terminated; results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Wisconsin, Madison | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2018-04-20